Home / Resource Library / Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD agent, + rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up ResultsGolcadomide (GOLCA), a potential, first-in-class, oral CELMoD agent, + rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results ASH 2025